CONCORDIA RX Trademark
Trademark Overview
On Thursday, May 16, 2024, a trademark application was filed for CONCORDIA RX with the United States Patent and Trademark Office. The USPTO has given the CONCORDIA RX trademark a serial number of 98553736. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, May 16, 2024. This trademark is owned by Concordia Pharmaceuticals Inc., S.à.r.L. The CONCORDIA RX trademark is filed in the Pharmaceutical Products category with the following description:
a full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
General Information
| Serial Number | 98553736 |
| Word Mark | CONCORDIA RX |
| Filing Date | Thursday, May 16, 2024 |
| Status | 630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER |
| Status Date | Thursday, May 16, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of the words "CONCORDIA RX", wherein both terms share a common "R" and the "X" is formed by the rightmost leg of the "R" and a diagonal line crossing it. |
| Goods and Services | a full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids) |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 16, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | Tuesday, February 28, 2017 |
| First Use In Commerce Date | Tuesday, February 28, 2017 |
Trademark Owner History
| Party Name | Concordia Pharmaceuticals Inc., S.à.r.L |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Luxembourg L-1610
LU |
Trademark Events
| Event Date | Event Description |
| Thursday, May 16, 2024 | NEW APPLICATION ENTERED |
| Monday, November 18, 2024 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Monday, November 18, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
